RBC Capital Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Cuts Target Price to $108

Moomoo NewsJan 7 09:35 ET · Ratings

RBC Trims Price Target on Intra-Cellular Therapies to $108 From $112, Keeps Outperform Rating

MT NewswiresJan 7 07:08 ET · Ratings

Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswireJan 6 08:00 ET

Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results

Analyst UpgradesDec 31, 2024 08:15 ET

Intra-Cellular Therapies' (NASDAQ:ITCI) Investors Will Be Pleased With Their Stellar 177% Return Over the Last Five Years

Simply Wall StDec 30, 2024 06:23 ET

When Will Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Turn A Profit?

Yahoo FinanceDec 28, 2024 09:41 ET